Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Information Dissemination | 15 | 2024 | 187 | 5.370 |
Why?
|
| Informed Consent | 9 | 2024 | 341 | 1.900 |
Why?
|
| Bioethics | 6 | 2020 | 70 | 1.550 |
Why?
|
| Databases, Genetic | 3 | 2019 | 470 | 1.510 |
Why?
|
| Disabled Persons | 3 | 2020 | 99 | 1.480 |
Why?
|
| Confidentiality | 5 | 2019 | 101 | 1.220 |
Why?
|
| Genetic Testing | 8 | 2024 | 994 | 1.170 |
Why?
|
| Public Policy | 6 | 2016 | 51 | 1.160 |
Why?
|
| Medical Informatics | 5 | 2019 | 107 | 1.140 |
Why?
|
| Direct-To-Consumer Screening and Testing | 2 | 2022 | 13 | 0.900 |
Why?
|
| Privacy | 2 | 2021 | 26 | 0.870 |
Why?
|
| Stakeholder Participation | 3 | 2019 | 24 | 0.840 |
Why?
|
| Health Equity | 1 | 2024 | 55 | 0.830 |
Why?
|
| Embryo Research | 4 | 2009 | 9 | 0.800 |
Why?
|
| Genetic Research | 2 | 2019 | 56 | 0.750 |
Why?
|
| Computer Security | 2 | 2018 | 26 | 0.750 |
Why?
|
| Ethics Consultation | 4 | 2016 | 28 | 0.740 |
Why?
|
| Genetic Privacy | 2 | 2018 | 40 | 0.730 |
Why?
|
| Mentoring | 1 | 2022 | 75 | 0.710 |
Why?
|
| Genetics | 1 | 2020 | 25 | 0.700 |
Why?
|
| Biomedical Research | 4 | 2019 | 517 | 0.700 |
Why?
|
| Mentors | 1 | 2022 | 145 | 0.700 |
Why?
|
| Patents as Topic | 2 | 2017 | 19 | 0.700 |
Why?
|
| Scholarly Communication | 1 | 2020 | 7 | 0.690 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 334 | 0.690 |
Why?
|
| Ethics, Clinical | 2 | 2022 | 77 | 0.680 |
Why?
|
| Embryonic Stem Cells | 3 | 2009 | 172 | 0.660 |
Why?
|
| Personally Identifiable Information | 1 | 2018 | 1 | 0.630 |
Why?
|
| Biomedical Technology | 1 | 2019 | 35 | 0.630 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 69 | 0.630 |
Why?
|
| Humans | 59 | 2024 | 123053 | 0.620 |
Why?
|
| Genotype | 1 | 2024 | 2533 | 0.610 |
Why?
|
| Mental Health | 1 | 2021 | 345 | 0.590 |
Why?
|
| Ethicists | 4 | 2022 | 41 | 0.580 |
Why?
|
| Schools | 1 | 2019 | 221 | 0.580 |
Why?
|
| United States | 19 | 2021 | 10646 | 0.580 |
Why?
|
| Parents | 4 | 2024 | 1031 | 0.580 |
Why?
|
| Health Policy | 2 | 2019 | 213 | 0.580 |
Why?
|
| Public Health | 1 | 2019 | 260 | 0.560 |
Why?
|
| Homocysteine | 1 | 2017 | 121 | 0.560 |
Why?
|
| Physician-Patient Relations | 3 | 2024 | 428 | 0.550 |
Why?
|
| Patients | 3 | 2018 | 121 | 0.550 |
Why?
|
| Autistic Disorder | 1 | 2020 | 346 | 0.550 |
Why?
|
| Communication | 3 | 2018 | 513 | 0.530 |
Why?
|
| Public Opinion | 1 | 2016 | 56 | 0.530 |
Why?
|
| Federal Government | 1 | 2016 | 15 | 0.530 |
Why?
|
| Minors | 1 | 2015 | 5 | 0.520 |
Why?
|
| Clinical Medicine | 1 | 2016 | 21 | 0.520 |
Why?
|
| Internationality | 1 | 2016 | 129 | 0.510 |
Why?
|
| Parental Consent | 1 | 2015 | 23 | 0.510 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 148 | 0.500 |
Why?
|
| Decision Making | 4 | 2024 | 651 | 0.490 |
Why?
|
| Research Subjects | 1 | 2015 | 55 | 0.490 |
Why?
|
| Physician's Role | 2 | 2024 | 164 | 0.490 |
Why?
|
| Moral Obligations | 2 | 2013 | 75 | 0.480 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.470 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2009 | 133 | 0.470 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.470 |
Why?
|
| Quality Improvement | 1 | 2020 | 626 | 0.470 |
Why?
|
| Advisory Committees | 4 | 2009 | 148 | 0.460 |
Why?
|
| Vaccination | 1 | 2019 | 947 | 0.460 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 861 | 0.450 |
Why?
|
| Internship and Residency | 1 | 2024 | 1158 | 0.450 |
Why?
|
| Health Care Rationing | 1 | 2014 | 58 | 0.430 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 1081 | 0.430 |
Why?
|
| Disclosure | 4 | 2024 | 154 | 0.430 |
Why?
|
| Blood Glucose | 1 | 2017 | 1119 | 0.430 |
Why?
|
| Truth Disclosure | 1 | 2014 | 103 | 0.410 |
Why?
|
| Pandemics | 1 | 2020 | 1099 | 0.410 |
Why?
|
| Fear | 1 | 2014 | 201 | 0.410 |
Why?
|
| Policy Making | 2 | 2019 | 59 | 0.400 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2014 | 130 | 0.400 |
Why?
|
| Treatment Refusal | 1 | 2013 | 77 | 0.400 |
Why?
|
| Ventricular Function | 1 | 2013 | 92 | 0.400 |
Why?
|
| Continuity of Patient Care | 1 | 2014 | 154 | 0.400 |
Why?
|
| Polycystic Kidney, Autosomal Recessive | 1 | 2012 | 9 | 0.390 |
Why?
|
| Genomics | 7 | 2024 | 1475 | 0.390 |
Why?
|
| Preimplantation Diagnosis | 1 | 2012 | 22 | 0.390 |
Why?
|
| Fetal Viability | 1 | 2012 | 29 | 0.390 |
Why?
|
| Neurosciences | 2 | 2024 | 50 | 0.390 |
Why?
|
| Guidelines as Topic | 2 | 2009 | 197 | 0.370 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1084 | 0.370 |
Why?
|
| Neoplasms | 5 | 2024 | 2758 | 0.370 |
Why?
|
| Oncologists | 2 | 2023 | 29 | 0.360 |
Why?
|
| Algorithms | 1 | 2017 | 1592 | 0.350 |
Why?
|
| Fertilization in Vitro | 1 | 2012 | 189 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1751 | 0.340 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 280 | 0.340 |
Why?
|
| Patient Discharge | 1 | 2014 | 486 | 0.340 |
Why?
|
| Government Regulation | 1 | 2009 | 42 | 0.320 |
Why?
|
| Information Technology | 2 | 2019 | 9 | 0.320 |
Why?
|
| Patient Selection | 1 | 2013 | 684 | 0.320 |
Why?
|
| Chimera | 1 | 2009 | 87 | 0.320 |
Why?
|
| Community Participation | 2 | 2019 | 44 | 0.310 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 76 | 0.310 |
Why?
|
| Patient Participation | 4 | 2023 | 220 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1230 | 0.290 |
Why?
|
| Physicians | 2 | 2018 | 583 | 0.290 |
Why?
|
| Ethical Analysis | 2 | 2019 | 48 | 0.290 |
Why?
|
| Heart-Assist Devices | 2 | 2013 | 1026 | 0.280 |
Why?
|
| Embryo, Mammalian | 2 | 2009 | 452 | 0.270 |
Why?
|
| Policy | 2 | 2024 | 34 | 0.270 |
Why?
|
| Autopsy | 2 | 2016 | 110 | 0.260 |
Why?
|
| Ethics, Medical | 4 | 2016 | 395 | 0.260 |
Why?
|
| Bioethical Issues | 1 | 2005 | 21 | 0.250 |
Why?
|
| Cybernetics | 1 | 2005 | 1 | 0.240 |
Why?
|
| Embryo Disposition | 1 | 2005 | 5 | 0.240 |
Why?
|
| Legislation, Medical | 1 | 2005 | 13 | 0.240 |
Why?
|
| Adoption | 1 | 2005 | 16 | 0.240 |
Why?
|
| Expert Testimony | 1 | 2005 | 34 | 0.240 |
Why?
|
| Managed Care Programs | 1 | 2005 | 61 | 0.240 |
Why?
|
| Goals | 1 | 2005 | 128 | 0.240 |
Why?
|
| Hospitals, Voluntary | 1 | 2004 | 4 | 0.240 |
Why?
|
| Biological Specimen Banks | 1 | 2005 | 52 | 0.230 |
Why?
|
| Professional Role | 1 | 2005 | 57 | 0.230 |
Why?
|
| Ecosystem | 1 | 2024 | 76 | 0.230 |
Why?
|
| Embryo Transfer | 1 | 2005 | 83 | 0.230 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2024 | 7 | 0.230 |
Why?
|
| Stem Cells | 1 | 2009 | 700 | 0.230 |
Why?
|
| Insurance Benefits | 1 | 2004 | 3 | 0.230 |
Why?
|
| Medically Uninsured | 1 | 2004 | 73 | 0.220 |
Why?
|
| HIV Infections | 1 | 2015 | 1855 | 0.220 |
Why?
|
| Neurophysiology | 1 | 2023 | 20 | 0.220 |
Why?
|
| Terminology as Topic | 1 | 2005 | 229 | 0.210 |
Why?
|
| Hospital Costs | 1 | 2004 | 178 | 0.210 |
Why?
|
| Insurance, Health | 1 | 2004 | 138 | 0.210 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2022 | 14 | 0.210 |
Why?
|
| Insurance Coverage | 1 | 2004 | 121 | 0.200 |
Why?
|
| Health Insurance Portability and Accountability Act | 2 | 2017 | 19 | 0.200 |
Why?
|
| Bangladesh | 2 | 2022 | 20 | 0.200 |
Why?
|
| General Surgery | 1 | 2024 | 203 | 0.200 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 375 | 0.190 |
Why?
|
| National Institute of Mental Health (U.S.) | 1 | 2021 | 13 | 0.190 |
Why?
|
| Metabolic Diseases | 1 | 2022 | 130 | 0.180 |
Why?
|
| Genetic Counseling | 2 | 2022 | 225 | 0.180 |
Why?
|
| RNA | 1 | 2024 | 570 | 0.180 |
Why?
|
| Surgeons | 1 | 2024 | 248 | 0.170 |
Why?
|
| Heart Failure | 1 | 2013 | 2127 | 0.170 |
Why?
|
| Coroners and Medical Examiners | 2 | 2016 | 15 | 0.170 |
Why?
|
| Ownership | 1 | 2019 | 30 | 0.170 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 507 | 0.170 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 271 | 0.160 |
Why?
|
| Military Personnel | 1 | 2020 | 208 | 0.150 |
Why?
|
| Ethics Committees, Clinical | 2 | 2016 | 16 | 0.150 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 42 | 0.140 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 51 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.130 |
Why?
|
| Hospital Administrators | 1 | 2016 | 8 | 0.130 |
Why?
|
| State Government | 1 | 2015 | 29 | 0.130 |
Why?
|
| Chemoprevention | 1 | 2015 | 57 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3074 | 0.120 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 92 | 0.120 |
Why?
|
| Professional Competence | 2 | 2014 | 97 | 0.120 |
Why?
|
| Radiation Oncology | 1 | 2014 | 23 | 0.120 |
Why?
|
| Politics | 2 | 2005 | 58 | 0.120 |
Why?
|
| Cadaver | 2 | 2016 | 129 | 0.120 |
Why?
|
| Female | 9 | 2024 | 65520 | 0.120 |
Why?
|
| Orbital Neoplasms | 1 | 2014 | 65 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 715 | 0.110 |
Why?
|
| Radiotherapy | 1 | 2014 | 135 | 0.110 |
Why?
|
| Licensure | 1 | 2014 | 15 | 0.110 |
Why?
|
| Exome | 1 | 2018 | 1038 | 0.110 |
Why?
|
| Forecasting | 2 | 2019 | 354 | 0.110 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3370 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 408 | 0.110 |
Why?
|
| Certification | 1 | 2014 | 67 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 826 | 0.110 |
Why?
|
| Writing | 1 | 2014 | 63 | 0.110 |
Why?
|
| Clinical Decision-Making | 1 | 2014 | 265 | 0.100 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 641 | 0.100 |
Why?
|
| Rhabdomyosarcoma | 1 | 2014 | 200 | 0.100 |
Why?
|
| Brain | 1 | 2023 | 2961 | 0.100 |
Why?
|
| Shock, Cardiogenic | 1 | 2013 | 187 | 0.090 |
Why?
|
| Adolescent | 5 | 2024 | 19096 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2013 | 437 | 0.090 |
Why?
|
| Male | 8 | 2024 | 60073 | 0.090 |
Why?
|
| Research Embryo Creation | 1 | 2009 | 1 | 0.080 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 593 | 0.080 |
Why?
|
| Financing, Government | 1 | 2009 | 30 | 0.080 |
Why?
|
| Ethics Committees, Research | 1 | 2009 | 33 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2009 | 63 | 0.080 |
Why?
|
| Ethics, Research | 1 | 2009 | 50 | 0.080 |
Why?
|
| Adult | 7 | 2024 | 29006 | 0.080 |
Why?
|
| Risk Factors | 2 | 2022 | 10012 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 238 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 3665 | 0.070 |
Why?
|
| Social Responsibility | 2 | 2019 | 79 | 0.070 |
Why?
|
| Quality of Life | 2 | 2013 | 1928 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 218 | 0.070 |
Why?
|
| Committee Membership | 1 | 2005 | 4 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2009 | 496 | 0.060 |
Why?
|
| Dissent and Disputes | 1 | 2005 | 31 | 0.060 |
Why?
|
| Publications | 1 | 2005 | 33 | 0.060 |
Why?
|
| Biotechnology | 1 | 2005 | 55 | 0.060 |
Why?
|
| Contract Services | 1 | 2005 | 3 | 0.060 |
Why?
|
| Lawyers | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ethics, Institutional | 1 | 2005 | 13 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 2479 | 0.060 |
Why?
|
| Fees and Charges | 1 | 2004 | 10 | 0.060 |
Why?
|
| DNA | 1 | 2010 | 1589 | 0.060 |
Why?
|
| Infant | 2 | 2016 | 12355 | 0.060 |
Why?
|
| Cryopreservation | 1 | 2005 | 82 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2005 | 144 | 0.060 |
Why?
|
| Cell Line | 1 | 2009 | 2769 | 0.060 |
Why?
|
| Prejudice | 1 | 2004 | 38 | 0.060 |
Why?
|
| Young Adult | 3 | 2024 | 8835 | 0.060 |
Why?
|
| Social Justice | 1 | 2004 | 55 | 0.050 |
Why?
|
| Atrophy | 1 | 2024 | 226 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2004 | 105 | 0.050 |
Why?
|
| Research | 1 | 2005 | 263 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 3562 | 0.050 |
Why?
|
| Research Personnel | 1 | 2024 | 117 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 72 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2022 | 107 | 0.050 |
Why?
|
| Phosphates | 1 | 2022 | 111 | 0.050 |
Why?
|
| Exploratory Behavior | 1 | 2022 | 52 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 500 | 0.050 |
Why?
|
| Child | 4 | 2024 | 24226 | 0.050 |
Why?
|
| Creatinine | 1 | 2022 | 380 | 0.040 |
Why?
|
| Family | 1 | 2024 | 569 | 0.040 |
Why?
|
| Intellectual Property | 1 | 2019 | 8 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 58 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7159 | 0.040 |
Why?
|
| California | 1 | 2019 | 127 | 0.040 |
Why?
|
| Attitude | 1 | 2019 | 118 | 0.040 |
Why?
|
| Trust | 1 | 2019 | 75 | 0.040 |
Why?
|
| Pedigree | 1 | 2022 | 1576 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 95 | 0.040 |
Why?
|
| Information Services | 1 | 2017 | 22 | 0.040 |
Why?
|
| Middle Aged | 4 | 2019 | 25987 | 0.040 |
Why?
|
| Calcium | 1 | 2022 | 1095 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2018 | 214 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2013 | 12119 | 0.030 |
Why?
|
| Consent Forms | 1 | 2016 | 23 | 0.030 |
Why?
|
| Prevalence | 1 | 2022 | 2404 | 0.030 |
Why?
|
| Death | 1 | 2016 | 70 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 374 | 0.030 |
Why?
|
| Social Media | 1 | 2017 | 109 | 0.030 |
Why?
|
| Health Facility Merger | 1 | 2015 | 10 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 95 | 0.030 |
Why?
|
| Models, Organizational | 1 | 2015 | 40 | 0.030 |
Why?
|
| North America | 1 | 2014 | 239 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 93 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2014 | 3316 | 0.020 |
Why?
|
| Consultants | 1 | 2005 | 10 | 0.020 |
Why?
|
| Hospital Administration | 1 | 2005 | 23 | 0.010 |
Why?
|
| Conflict of Interest | 1 | 2005 | 67 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8109 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 13881 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19088 | 0.010 |
Why?
|